Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-062
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
PVP003 is a tablet formulation of **TAK-062** (formerly known as Kuma062), a recombinant, computationally engineered gluten-degrading enzyme (glutenase). Developed by PvP Biologics and later acquired by Takeda, the drug is designed to treat celiac disease by breaking down immune-reactive gluten peptides in the stomach before they reach the small intestine. The enzyme is a highly potent prolyl endopeptidase (PEP) derived from *Alicyclobacillus sendaiensis* (kumamolisin-As), engineered to be active at the low pH of the stomach and highly resistant to proteolysis by pepsin. Clinical studies, including NCT03701555, have evaluated PVP003 alongside other formulations (PVP001 liquid and PVP002 capsules) to determine safety, tolerability, and efficacy in degrading gluten in healthy volunteers and patients with celiac disease.
- Other names
- Kuma062Kuma-062Kuma 062KumaMax
Beyond the preview
Go deeper on TAK-062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-062.